Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03089320 · ClinicalTrials.gov registry record · NA
Financial Incentives, Randomization With Stepped Treatment Trial
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 120
- Enrollment target
NCT03089320: Completed NA study, sponsored by Yale University.
NCT03089320 is a NA study that has completed, run by Yale University. The registered enrollment target is 120 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03089320, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
Study Summary
The investigators plan to determine the effectiveness of contingency management (CM) plus stepped care for unhealthy alcohol use in HIV-positive patients.
Primary Outcome
Recorded via web based time-line followback
Interventions
- BEHAVIORAL Motivational Enhancement Therapy
- BEHAVIORAL Contingency Management Counseling
- BEHAVIORAL Addiction Physician Management
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2023-04-01 |
| Phase | NA |
What the finished NCT03089320 record still lists
NCT03089320 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 3 interventions - of which Motivational Enhancement Therapy is the first listed.
NCT03089320 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03089320 about?
NCT03089320 is a clinical study titled "Financial Incentives, Randomization With Stepped Treatment Trial". The investigators plan to determine the effectiveness of contingency management (CM) plus stepped care for unhealthy alcohol use in HIV-positive patients.
What is the current status of trial NCT03089320?
This trial is currently completed. It is a NA study. The enrollment target is 120 participants. The study started on 2018-05-01. Estimated completion is 2023-04-01.
What interventions are being tested in trial NCT03089320?
The interventions under investigation include: Motivational Enhancement Therapy (BEHAVIORAL), Contingency Management Counseling (BEHAVIORAL), Addiction Physician Management (BEHAVIORAL).
Who is sponsoring clinical trial NCT03089320?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03089320's enrollment target sits among peer trials
120 762nd of 2000 higher than 1,198 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI